SCYX — SCYNEXIS, Inc.
$3.21
$-0.12 (-3.60%)
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Market Cap
$31.95M
Forward P/E
-1.6x
52-Week Range
N/A
SCYX Price History
Revenue vs. Net Income
$20.6M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$5.3M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-15.8%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
6.1x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.2%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+2.9%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
